Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
NCT06649422 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 36
Last updated 2024-10-18
Summary
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed Ph-negative B-ALL.
Conditions
- Leukemia, Lymphocytic, Acute, Adult
Interventions
- DRUG
-
The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
Sponsors & Collaborators
-
Shandong Provincial Hospital
collaborator OTHER_GOV -
The Affiliated Hospital of Qingdao University
collaborator OTHER -
Tangshan Central Hospital
collaborator OTHER -
Affiliated Central Hospital of Shandong First Medical University
collaborator UNKNOWN -
Yantai Yuhuangding Hospital
collaborator OTHER -
Qilu Hospital of Shandong University (Qingdao)
collaborator OTHER -
Qingdao Central Hospital
collaborator OTHER -
Qingdao Municipal Hospital
collaborator OTHER -
The Affiliated Hospital of Jining Medical University and Zaozhuang City
collaborator UNKNOWN -
Affiliated Hospital of Binzhou Medical College
collaborator UNKNOWN -
Linyi People's Hospital
collaborator OTHER -
The Second Hospital of Shandong University
collaborator OTHER -
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
collaborator OTHER -
Shandong First Medical University
collaborator OTHER -
Shengli Oilfield Hospital
collaborator OTHER -
Heze Municipal Hospital
collaborator OTHER -
Zibo Central Hospital
collaborator OTHER_GOV -
Zaozhuang Municipal Hospital
collaborator OTHER -
Weihai Municipal Hospital
collaborator OTHER -
Shandong University
lead OTHER
Principal Investigators
-
Chunyan Ji, Doctor · Qilu Hospital of Shandong University
Eligibility
- Min Age
- 15 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-01
- Primary Completion
- 2025-12-31
- Completion
- 2027-12-31
More Related Trials
-
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02013167 ·Status: TERMINATED ·Phase: PHASE3
-
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
NCT06742515 ·Status: RECRUITING ·Phase: PHASE2
-
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
NCT06250959 ·Status: RECRUITING ·Phase: PHASE2
-
Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
NCT07199855 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
NCT04554485 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
NCT06481241 ·Status: RECRUITING ·Phase: NA
-
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation
NCT06504186 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
NCT06930105 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
NCT06507514 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
NCT06649006 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
NCT05931757 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
NCT06559644 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
NCT03367299 ·Status: COMPLETED ·Phase: PHASE2
-
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
NCT06075238 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02143414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179 ·Status: COMPLETED ·Phase: PHASE2
-
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
NCT04524455 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT07107204 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057 ·Status: RECRUITING ·Phase: PHASE2/PHASE3